Search - tctmd.com

Displaying 21 - 40 of 59

Sort: Relevancy | Date

News Daily News

PROTECT AF at 4 Years: LAA Closure Maintains Efficacy Over Warfarin

Caitlin E. Cox

November 19, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

Presentation TCT 2014

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Vivek Y. Reddy

September 13, 2014

Presentation LAA 2014

Watchman: Registry Data from the “Real-World”

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Case 2: Watchman Implantation

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Novel LAA Closure Technologies on the Horizon

Presenter: Vivek Y. Reddy

July 17, 2014

Presentation LAA 2014

Electrical Approaches to AF Ablation: Acute & Sustained Success, Complications

Presenter: Vivek Y. Reddy

July 17, 2014

Presentation TCT 2013

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: Vivek Y. Reddy

October 29, 2013

Presentation TCT 2013

Pro(2)

Presenter: Vivek Reddy

October 28, 2013

Presentation TCT 2013

LAA Closure in Combination with Ablation: Rationale and Results

Presenter: Vivek Reddy

October 27, 2013

News Daily News

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

Yael L. Maxwell

May 17, 2013

News Daily News

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

Yael L. Maxwell

May 17, 2013

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

News Daily News

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

Yael L. Maxwell

April 12, 2013

News Daily News

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

Yael L. Maxwell

April 12, 2013

Advertisement

PROTECT AF at 4 Years: LAA Closure Maintains Efficacy Over Warfarin

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Watchman: Registry Data from the “Real-World”

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Case 2: Watchman Implantation

Novel LAA Closure Technologies on the Horizon

Electrical Approaches to AF Ablation: Acute & Sustained Success, Complications

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Pro(2)

LAA Closure in Combination with Ablation: Rationale and Results

PROTECT AF: Los Resultados a los 4 Años revelan la Superioridad del Watchman sobre la Warfarina contra la FA

PROTECT AF: 4-Year Results Show Superiority of Watchman Over Warfarin for A-fib

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content